Union members and supporters gathered outside the Peterborough Regional Health Centre for a media conference on Thursday, to symbolize and bring awareness to Ontario’s health care crisis.

Opthea's lead compound, sozinibercept, targets VEGF-C/D and is in Phase 3 trials for wet AMD. Read more to see why I'm neutral on OPT stock.